1.	Multicenter Selective Lymphadenectomy Trial II (MSLT-II) Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: 18 to 75 Sponsor: NCI, Other Protocol IDs: MSLT-II, NIH P01 CA029605, NCT00297895
2.	Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 11-002177, NCI-2013-00645, NCT01826864
3.	Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ALS-357-001, NCT00701987
4.	Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: I 191511, NCI-2011-03568, NCT01522820
5.	Effects of GM-CSF and/or Incomplete Freund's Adjuvant on Immune Cells at or Around the Tumor Site in Patients With Stage I or Stage II Melanoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment Status: Active Age: 18 to 85 Sponsor: NCI Protocol IDs: UVACC-MEL-38, UVACC-14499, UVACC-HIC-8380
6.	Pilot Study of IFN a2b for Melanoma Patients Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-067, NCT00871533